Risankizumab: A Complete Medical Overview

Risankizumab is a prescription biologic medicine used to treat certain immune-mediated inflammatory diseases, including plaque psoriasis, psoriatic arthritis, and Crohn’s disease. It works by blocking interleukin-23, a protein involved in inflammation, and is usually given on a planned schedule under specialist supervision.

Overview: what risankizumab is and what it treats

Risankizumab is a biologic medicine that helps control inflammation caused by an overactive immune response. It is used for certain chronic inflammatory conditions, most commonly moderate to severe plaque psoriasis, active psoriatic arthritis, and Crohn’s disease in appropriate patients. Rather than broadly suppressing the immune system, it targets a specific inflammatory pathway.

The medicine works by blocking interleukin-23, often shortened to IL-23. This signaling protein plays an important role in driving inflammation in several immune-mediated diseases. By reducing IL-23 activity, risankizumab can help lessen symptoms, improve skin or bowel inflammation, and support longer-term disease control.

Risankizumab is not a cure, and it does not work instantly. Many people need ongoing treatment and follow-up to see the full benefit. A specialist will decide whether it is suitable based on diagnosis, previous treatments, general health, infection risk, and treatment goals.

How risankizumab works in the body

Immune-mediated conditions develop when the body’s defense system becomes overactive and attacks healthy tissues or keeps inflammation switched on. In plaque psoriasis, this can lead to thick, scaly skin plaques. In psoriatic arthritis, it can contribute to joint pain and swelling. In Crohn’s disease, it can drive inflammation in the digestive tract.

Risankizumab is a monoclonal antibody, a type of engineered protein designed to bind to a precise target. Its target is part of IL-23, which helps activate inflammatory cells. When this pathway is blocked, the immune signals linked to ongoing inflammation are reduced, which may improve symptoms and help protect tissues from further damage.

This targeted approach is one reason biologic therapies are different from traditional anti-inflammatory medicines. Still, because the immune system is involved, treatment requires monitoring for infections and other potential side effects. Patients should use it only under the care of a qualified clinician familiar with biologic therapy.

Conditions commonly treated with risankizumab

Risankizumab is approved in many regions for plaque psoriasis, psoriatic arthritis, and Crohn’s disease, although exact approvals can vary by country. In plaque psoriasis, it is usually considered for adults with moderate to severe disease, especially when topical treatments alone are not enough or when the condition significantly affects daily life. People with psoriasis may be assessed for biologic therapy when skin involvement is extensive or persistent.

In psoriatic arthritis, risankizumab may help reduce joint symptoms and improve physical function. It may be considered when symptoms remain active despite other therapies. The treatment plan may include physical therapy, pain management strategies, and sometimes other medicines depending on the person’s needs.

In Crohn’s disease, risankizumab may be used in selected adults with moderate to severe disease, often when inflammation has not responded well enough to other treatments. Because symptoms can overlap with other digestive disorders, a careful diagnosis is important. Patients being evaluated for inflammatory bowel conditions may also undergo testing and specialist review similar to that used for Crohn’s disease.

Doctors do not prescribe risankizumab for every inflammatory complaint. The medicine is reserved for defined conditions where its benefits and risks have been studied. The decision also depends on disease severity, treatment history, associated conditions, and patient preferences.

How it is given and what treatment involves

Risankizumab is given on a scheduled basis rather than taken as a daily tablet. Depending on the condition being treated, it may be administered by injection under the skin or, in some settings and phases of treatment, by intravenous infusion. The exact schedule and setting depend on the approved use and the treating specialist’s plan.

Before treatment starts, the care team usually confirms the diagnosis, reviews previous medicines, and checks for problems that could make biologic therapy less suitable. This often includes screening for infections such as tuberculosis, reviewing recent illness, and checking whether routine vaccinations are up to date. Laboratory tests may also be used before and during treatment.

People receiving infusion-based care may have treatment in a supervised setting such as infusion therapy. Others may receive instruction on injections, storage, and timing. Missing doses or stopping treatment without medical advice can affect disease control, so patients should ask their team what to do if a dose is delayed.

Follow-up appointments are important. Doctors assess whether symptoms are improving, whether side effects have appeared, and whether the medicine continues to be the best option. In some cases, treatment may be adjusted or changed if the response is incomplete.

Benefits, side effects, and safety considerations

The main benefit of risankizumab is targeted control of inflammation. For people with psoriasis, this may mean clearer skin and less itching or scaling. For psoriatic arthritis, it may help reduce joint inflammation and improve movement. For Crohn’s disease, it may help reduce digestive symptoms and support healing of inflamed tissue.

Like all medicines, risankizumab can cause side effects. Commonly reported effects may include upper respiratory symptoms, headache, tiredness, or reactions at the injection site. Some people experience mild infections such as colds. Not everyone has side effects, and many tolerate treatment well, but any new or unusual symptoms should be discussed with a clinician.

Because risankizumab affects immune signaling, infections are an important safety consideration. Patients should tell their doctor promptly about fever, persistent cough, shortness of breath, painful urination, severe diarrhea, or wounds that do not heal. Treatment may need to be delayed or paused if an active infection develops.

Allergic reactions are uncommon but require urgent medical attention if they occur. Warning signs may include widespread rash, facial swelling, wheezing, or trouble breathing. Doctors also consider vaccine timing, pregnancy plans, other immune-suppressing medicines, and medical history before prescribing biologic treatment. For some patients with inflammatory bowel symptoms, evaluation may involve advanced gastroenterology care to guide safe long-term management.

Who may or may not be a good candidate

Risankizumab may be a good option for adults with confirmed inflammatory disease who need more than topical therapy, standard oral medicines, or earlier biologics have not worked well enough. Suitability depends on disease type, severity, previous response to treatment, and the balance between expected benefit and potential risk.

It may not be the right choice for everyone. Active infections, certain unresolved test results, or a history that raises concern about immunosuppression may lead a doctor to postpone or avoid treatment. The care team will also review other medicines, as well as personal factors such as travel plans, vaccination status, and ability to attend follow-up.

Pregnancy and breastfeeding decisions should always be individualized. Anyone who is pregnant, planning pregnancy, or breastfeeding should discuss this with their specialist before starting or continuing risankizumab. The same applies to people with a history of recurrent infections or those scheduled for surgery.

Shared decision-making is important. Patients should understand why risankizumab is being recommended, how long it may take to work, what monitoring is needed, and what alternatives exist, including supportive care, other biologics, and disease-specific treatments such as dermatology follow-up for complex skin disease.

Practical self-care during treatment

Self-care does not replace medical treatment, but it can support better disease control and quality of life. Patients should keep all appointments, follow instructions for dosing and storage, and inform the care team about any side effects or infections. It can help to keep a simple symptom diary, including flare patterns, fatigue, skin changes, bowel symptoms, or joint pain.

General health measures remain important while using biologic therapy. These include good hand hygiene, staying up to date with doctor-recommended vaccines, eating a balanced diet, and getting enough rest. Smoking cessation is especially important for people with Crohn’s disease and may also benefit overall inflammatory health.

People with psoriasis may benefit from gentle skin care, fragrance-free moisturizers, and avoiding personal triggers when possible. Those with inflammatory bowel disease may need individualized nutrition advice based on symptoms and nutritional status. Joint symptoms may improve with guided exercise or physical therapy, but activity should be adapted during flares.

Patients should not start new over-the-counter supplements, herbal products, or immune-targeting medicines without checking first. Even nonprescription products can affect treatment plans or complicate side-effect assessment. Good communication with the healthcare team is one of the most practical ways to stay safe.

When to seek medical care

Medical advice should be sought promptly if symptoms of the underlying disease are worsening despite treatment. Examples include spreading psoriasis plaques, increasing joint swelling or stiffness, ongoing abdominal pain, persistent diarrhea, rectal bleeding, unexplained weight loss, or severe fatigue. A doctor can assess whether the disease is flaring, whether another condition is present, or whether treatment needs adjustment.

Urgent medical care is important for signs of serious infection or allergic reaction. These include high fever, shaking chills, shortness of breath, chest pain, confusion, severe dehydration, facial swelling, widespread rash, or trouble breathing. Patients should also contact their doctor before surgery, after close exposure to certain infections, or if they think they may be pregnant.

Specialist review is also worthwhile if there are concerns about how the medicine is being administered, if doses have been missed, or if side effects are becoming difficult to manage. Near the end of the care pathway, some international patients may choose assessment at centers such as Acibadem International, where multidisciplinary specialists in JCI-accredited hospitals diagnose and treat complex inflammatory conditions.

Frequently asked questions

What is risankizumab used for?

Risankizumab is used to treat certain chronic inflammatory diseases, especially plaque psoriasis, psoriatic arthritis, and Crohn’s disease in appropriate patients. The exact approved uses can vary by country, so a specialist will confirm whether it is suitable for a specific condition.

Is risankizumab a steroid or chemotherapy?

No. Risankizumab is a biologic medicine, specifically a monoclonal antibody that targets the IL-23 pathway. It works differently from steroids and is not considered chemotherapy.

How long does risankizumab take to work?

Response time varies by condition and by person. Some patients notice improvement within the first weeks or months, while others need longer to see the full effect. Regular follow-up helps doctors judge whether the treatment is working well enough.

What are the most common side effects of risankizumab?

Common side effects may include mild upper respiratory symptoms, headache, tiredness, or injection-site reactions. Because it affects immune signaling, infections are an important consideration, so any fever or persistent illness should be reported to a doctor.

Do patients need tests before starting risankizumab?

Yes, screening is usually needed before treatment begins. Doctors often check for infections such as tuberculosis, review vaccination history, and may order blood tests depending on the person’s health and the condition being treated.

Can risankizumab be used during pregnancy or breastfeeding?

This decision should be individualized and discussed with a specialist. A doctor will consider disease control, alternative treatments, and available safety information before advising whether to start, continue, or pause therapy.

References

• U.S. Food and Drug Administration
• National Institute for Health and Care Excellence
• American Academy of Dermatology
• Crohn's & Colitis Foundation
• Arthritis Foundation

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.